EGFR and non-small cell lung carcinoma: The AURA3 trial [10] indicated that at the moment of progression to osimertinib in the second-line therapy, even 49% of NSCLC patients lost the T790M substitution and 21% acquired the tertiary EGFR mutations such as C797S or C797R.